A 62-year-old man was referred to our department with abdominal pain and diarrhea for 3 weeks on a background of previous branched endovascular repair for a thoracoabdominal aneurysm. A triple-phase computed tomography scan of his abdomen and pelvis showed a large aortocaval fistula caused by a type III endoleak from a dislodged superior mesenteric artery stent. He was successfully treated with a BeGraft (Bentley Innomed, Hechingen, Germany) by using an endovascular technique. (J Vasc Surg Cases and Innovative Techniques 2017;3:4–6.)

A triple-phase computed tomography scan of the thorax, abdomen, and pelvis showed dilated bowel loops measuring up to 6 cm (maximum transverse diameter) in the SMA territory. A dislodged SMA stent was noted causing a large type III endoleak with decompression into the inferior vena cava via a large ACF. The endoleak was arising from the junction of the branch with the connecting stent (Fig 1).

There was a marginal expansion of the sac in the interim period from 11 to 11.4 cm. The fistulation meant that the sac size did not increase significantly.

After an informed consent was obtained, the patient was brought forward for an endoluminal repair of the dislodged SMA stent as a semi-elective case. Access was gained via a left axillary cutdown. Because of the tortuous nature of the branches, the SMA stent was initially cannulated. The significant gap from the end of the stent to the native SMA made it difficult for traditional catheters to gain access. A steerable catheter was successfully used to bridge the gap to the native SMA. A 10-mm × 57-mm BeGraft (Bentley Innomed, Hechingen, Germany) was successfully deployed (Fig 2). Selective digital subtraction angiography runs of the SMA showed the type III endoleak was completely excluded. Delayed runs showed no filling of the ACF.

The patient made an uneventful recovery, with complete resolution of his symptoms, and was discharged home 2 days later. Repeat imaging showed sealing of the endoleak and no further fistula flow. The sac size had also stabilized at the 1-month follow-up computed tomography scan (Fig 3). At the 6-month follow-up, he was symptom free.

DISCUSSION

An ACF is a rare condition that was first described by James Syme in 1831.1 In a study reported by Akwei et al. ACF constitutes <6% of all arteriovenous fistulas.2 An erosion or spontaneous rupture of the AAA into the vena cava is the most common cause of an ACF.3,4 The incidence of an ACF in patients treated with an endoprosthesis for an aortic aneurysm repair is low.

Cardiac preload and venous hypertension are understood to be the sequelae from shunting of blood from a high-pressure arterial system into a low-pressure venous system. This may clinically manifest in some

References

1. Syme J. An essay on the disease called the white plague (thrills) of the stomach and intestines. London: Longman, Hurst, Rees, Orme, & Brown; 1831
2. Akwei K, Nadeem A, Lee J. Arteriovenous fistula after endovascular aortic aneurysm repair: a case report. J Vasc Surg Cases Innov Technol. 2017;3:46–9
3. Chaturvedi R, Tegtmeyer K, Giddens W. Anomalies of the aorto caval junction: the importance of the venous system in scaphoid vena cava syndrome. Tex Heart Inst J. 2004;31:34–40
4. Sturrock J, Thomson A, Connell S. Aorto caval fistula. Br J Surg. 1985;72:358–9
patients as an acute lower limb edema or hematuria caused by impaired renal perfusion.\textsuperscript{5,6} Lau et al\textsuperscript{5} have described these symptoms to be prevalent in 50\% to 80\% patients with a diagnosis of an ACF.

Leon et al\textsuperscript{7} mentions that the symptoms related to an arteriovenous fistula vary according to the size of the fistula. Patients with a small fistula could be asymptomatic.

Endovascular and conservative treatment options have been described in the surgical literature for management of ACF. The traditional approach for treatment of an ACF was an open surgical repair, which had a mortality rate of 30\%, particularly in patients with cardiac decompression.\textsuperscript{5} The first endovascular repair was performed by Beveridge et al\textsuperscript{8} in 1998, after which other authors have described successful treatment using endovascular techniques.

Van de Luijtgaarden et al\textsuperscript{9} say that in the absence of systemic repercussions, persistent ACFs caused by type II endoleak after EVAR may be managed conservatively and that favorable remodelling of the aneurysm sac might be possible.

In our case, the patient was symptomatic from the type III endoleak due to the dislodged SMA stent. This could have occurred as a result of remodelling of the aorta after aneurysm repair. The bowel symptoms were related to ischemia caused by alteration of arterial supply due to the stent dislodgment and may be related to the venous hypertension. Because the patient’s symptoms resolved immediately after the endovascular treatment, this was thought to be most likely cause.

The Bentley Innomed stent is an approved graft in Australia and New Zealand. These grafts are extremely versatile and became popular with the inability to access Atrium VI2 stent grafts (Atrium Medical Corp, Hudson, NH) in New Zealand.

In our case, an indirect approach was used to treat the ACF without using an endovenous stent. However a
covered endovenous stent or a direct embolization of the aortic sac by injecting Onyx glue (ev3 Endovascular, Inc, Plymouth, Minn) could be considered if there were an evidence of aortic sac expansion in the future.

CONCLUSIONS
A high degree of vigilance is required in patients presenting with atypical symptoms of abdominal pain. Timely diagnosis and management is important for treatment of an ACF because this has shown to improve patient outcomes. Endovascular treatment is possible for treatment of ACFs even after remodelling of the stent grafts after a previous EVAR.

REFERENCES
1. Syme J. Case of spontaneous varicose aneurysm. Edinb Med Surg J 1831;36:1045.
2. Akwei S, Altaf N, Tennant W, MacSweeney S, Braithwaite B. Emergency endovascular repair of aortocaval fistula—a single center experience. Vascular and Endovascular Surgery 2011;45:442-6.
3. Schmidt R, Bruns C, Walter M, Erasmi H. Aorto-caval fistula—an uncommon complication of infrarenal aortic aneurysms. Thorac Cardiovasc Surg 1994;42:208-11.
4. Guzzardi G, Fossaceca R, Divenuto I, Musiani A, Brustia P, Carriero A. Endovascular treatment of ruptured abdominal aortic aneurysm with aortocaval fistula. Cardiovasc Intervent Radiol 2010;33:853-6.
5. Lau LL, O’Reilly MJ, Johnston LC, Lee B. Endovascular stentgraft repair of primary aortocaval fistula with an abdominal aortoiliac aneurysm. J Vasc Surg 2001;33:425-8.
6. Maeda H, Umezawa H, Goshima M, Hattori T, Nakamura T, Takasaka A, et al. Surgery for ruptured abdominal aortic aneurysm with an aortocaval and iliac vein fistula. Surg Today 2007;37:445-8.
7. Leon LR Jr, Arslan B, Ley E, Labropoulos N. Endovascular therapy of spontaneous aortocaval fistulae associated with abdominal aortic aneurysms. Vascular 2007;15:35-40.
8. Beveridge CJ, Pleass HC, Chamberlain J, Wyatt MG, Rose JD. Aortoiliac aneurysm with arteriocaval fistula treated by a bifurcated endovascular stent-graft. Cardiovasc Intervent Radiol 1998;21:244-6.
9. Van de Luijtgaarden KM, Gonçalves FB, Rouwet EV, Hendriks JM, Raa ST, Verhagen HJ. Conservative management of persistent aortocaval fistula after endovascular aortic repair. J Vasc Surg 2015;61:1080-3.
10. Waldrop JL Jr, Dart BW 4th, Barker DE. Endovascular stent graft treatment of a traumatic aortocaval fistula. Ann Vasc Surg 2005;19:562-5.

Submitted May 21, 2016; accepted Sep 1, 2016.